Zhang Yun, Liang Mingming, Sun Chenyu, Qu Guangbo, Shi Tingting, Min Min, Wu Yile, Sun Yehuan
From the Department of Epidemiology and Health Statistics, School of Public Health, and.
Center for Evidence-Based Practice, Anhui Medical University.
Pancreas. 2019 Feb;48(2):142-150. doi: 10.1097/MPA.0000000000001226.
The aim of this study was to explore the relationship between statin use and the risk of pancreatic cancer.
Electronic databases were searched to identify relevant studies published until January 2018. The pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated with random-effects model. Subgroup analyses and sensitivity analysis were also conducted. Cochran Q test and I(2) statistic were used to evaluate the heterogeneity.
Twenty-six studies were included that contained more than 3 million participants and 170,000 pancreatic cancer patients. The overall result demonstrated a significant decrease in pancreatic cancer risk with statin use (RR, 0.84; 95% CI, 0.73-0.97; P = 0.000; I(2) = 84.4%). In subgroup analyses, nonsignificant association was detected between long-term statin use and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.86-1.11; P = 0.718; I(2) = 0.0%). Meanwhile, there was nonsignificant association between the use of lipophilic statins and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.84-1.15; P = 0.853; I(2) = 27.2%). No publication bias was found in this meta-analysis.
The overall result of this meta-analysis supports the hypothesis that statins have a protective effect on pancreatic cancer. Furthermore, high-quality randomized clinical trials and cohort studies are needed to confirm these findings.
本研究旨在探讨他汀类药物使用与胰腺癌风险之间的关系。
检索电子数据库以识别截至2018年1月发表的相关研究。采用随机效应模型计算合并相对风险（RRs）和95%置信区间（CIs）。还进行了亚组分析和敏感性分析。使用Cochran Q检验和I²统计量评估异质性。
纳入了26项研究，包含超过300万参与者和170,000例胰腺癌患者。总体结果显示，使用他汀类药物可使胰腺癌风险显著降低（RR，0.84；95% CI，0.73 - 0.97；P = 0.000；I² = 84.4%）。在亚组分析中，未检测到长期使用他汀类药物与胰腺癌风险之间存在显著关联（RR，0.98；95% CI，0.86 - 1.11；P = 0.718；I² = 0.0%）。同时，使用亲脂性他汀类药物与胰腺癌风险之间也无显著关联（RR，0.98；95% CI，0.84 - 1.15；P = 0.853；I² = 27.2%）。本荟萃分析未发现发表偏倚。
本荟萃分析的总体结果支持他汀类药物对胰腺癌具有保护作用这一假说。此外，需要高质量的随机临床试验和队列研究来证实这些发现。
